Abstract
Background: The aim of this study was to estimate the cost-effectiveness of injectable extended-release naltrexone (XR-NTX) compared with methadone maintenance and buprenorphine maintenance treatment (MMT and BMT, respectively) for adult males enrolled in treatment for opioid dependence in the United States from the perspective of state-level addiction treatment payers. Methods: A Markov model with daily time cycles was used to estimate the incremental cost per opioid-free day in a simulated cohort of adult males aged 18-65 over a 6-month period from the state health program perspective. Results: XR-NTX is predicted to be more effective and more costly than methadone or buprenorphine in our target population, with an incremental cost per opioid-free day gained relative to the next-most effective treatment (MMT) of $72. The cost-effectiveness of XR-NTX relative to MMT was driven by its effectiveness in deterring opioid use while receiving treatment. Conclusions: XR-NTX is a cost-effective medication for treating opioid dependence if state addiction treatment payers are willing to pay at least $72 per opioid-free day.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 226-231 |
| Number of pages | 6 |
| Journal | Substance Abuse |
| Volume | 36 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 3 2015 |
Bibliographical note
Publisher Copyright:© 2015 Taylor and Francis Group, LLC.
Keywords
- Cost-effectiveness
- XR-NTX
- opioid dependence
